A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

Inclusion Criteria:

- Eligible male and female subjects, aged 18 to 75 years

- Must have diagnosis of SLE with either the Systemic Lupus International Collaborating
Clinics (SLICC) criteria for SLE, or at least four of the 11 American College of
Rheumatology (ACR) classification criteria for SLE, of at least six months duration
prior to Screening

- SLEDAI-2K total score greater than or equal to (>=) 6 (including clinical SLEDAI
greater than or equal to (>=) 4) at Screening Visit

- And be positive for anti-double-stranded Deoxyribonucleic Acid (DNA) and/or
anti-nuclear antibody (ANA greater than or equal to (>=) 1:80) and/or anti-Smith
(anti-Sm) antibody at the time of Screening

- Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

- Subjects are not eligible for this study if they have active, clinically significant
interstitial lung disease or pulmonary arterial hypertension

- Proteinuria (urine protein to creatinine ratio [UPCR] > 4 mg/mg)

- Acutely worsened renal function

- Central nervous system SLE

- Or within two weeks prior to Screening or during Screening: use of oral
corticosteroids greater than (>) 30 mg daily prednisone equivalent

- Use of injectable corticosteroids, or change in dose of corticosteroids.

- Other protocol defined exclusion criteria could apply.